Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (81-90 of 436) with videos related to

Pageof 44
Sort By:
Blood Advances|June 26, 2026
RNA interference targeting factor XI: new and novel approachRichard C Becker
Journal of Thrombosis and Thrombolysis|January 8, 2016
Aspirin dosing frequency in the primary and secondary prevention of cardiovascular eventsJoonseok Kim, Richard C Becker
Journal of Thrombosis and Thrombolysis|April 25, 2012
Biomarker science: on a theme of personalized medicineRichard C Becker, Susan Smyth
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
DVT: a new era in anticoagulant therapyNigel Mackman, Richard C Becker
Journal of Thrombosis and Thrombolysis|October 25, 2008
Early career investigator's circle: identifying and nurturing the next generation of scientists and scientific writersRichard C Becker, David Sane
American Heart Journal|June 25, 2005
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part IIAnnemarie Armani, Richard C Becker
Journal of Thrombosis and Thrombolysis|October 22, 2008
Anticoagulant therapy during cardiopulmonary bypassMaryam Yavari, Richard C Becker
Circulation|April 11, 2014
A freeze on tailored antiplatelet therapy?Deepak Voora, Richard C Becker
Handbook of Experimental Pharmacology|August 25, 2012
PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosisSergio Leonardi, Richard C Becker
Circulation|June 3, 2015
Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapyRichard C Becker, Tarek Helmy
Pageof 44

Showing results (81-90 of 436) with videos related to

Sort By:
Pageof 44
Blood Advances|June 26, 2026
RNA interference targeting factor XI: new and novel approachRichard C Becker
Journal of Thrombosis and Thrombolysis|January 8, 2016
Aspirin dosing frequency in the primary and secondary prevention of cardiovascular eventsJoonseok Kim, Richard C Becker
Journal of Thrombosis and Thrombolysis|April 25, 2012
Biomarker science: on a theme of personalized medicineRichard C Becker, Susan Smyth
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
DVT: a new era in anticoagulant therapyNigel Mackman, Richard C Becker
Journal of Thrombosis and Thrombolysis|October 25, 2008
Early career investigator's circle: identifying and nurturing the next generation of scientists and scientific writersRichard C Becker, David Sane
American Heart Journal|June 25, 2005
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part IIAnnemarie Armani, Richard C Becker
Journal of Thrombosis and Thrombolysis|October 22, 2008
Anticoagulant therapy during cardiopulmonary bypassMaryam Yavari, Richard C Becker
Circulation|April 11, 2014
A freeze on tailored antiplatelet therapy?Deepak Voora, Richard C Becker
Handbook of Experimental Pharmacology|August 25, 2012
PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosisSergio Leonardi, Richard C Becker
Circulation|June 3, 2015
Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapyRichard C Becker, Tarek Helmy
Pageof 44